Effect of Binder Type and Binder Level on the Properties of Agglomerates Containing Lactose and Dibasic Calcium Phosphate Dihydrate - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Effect of Binder Type and Binder Level on the Properties of Agglomerates Containing Lactose and Dibasic Calcium Phosphate Dihydrate
The authors studied the effect of the combination of binders on the flow and compressibility characteristics of the agglomerates of binary combination of lactose and dibasic calcium phosphate dihydrate.


Pharmaceutical Technology
Volume 32, Issue 10, pp. 54-64

7. J.I. Wells, D.A. Bhatt, and K.A. Khan, "Improved Wet Massed Tableting using Plasticized Binder," J. Pharm. Pharmacol. 34 (suppl.), 46P (1982).

8. T. Abberger, "Influence of Binder Properties, Method of Addition, Powder Type and Operating Conditions on Fluid Melt Granulation and Resulting Tablet Properties," Pharmazie 56 (12), 949–952 (2001).

9. S.K. Joneja et al., "Investigating the Fundamental Effects of Binder on Pharmaceutical Tablet Performance," Drug Dev. Ind. Pharm. 25 (10), 129–135 (1999).

10. M.C. Gohel and P.D. Jogani, "Exploration of Melt Granulation Technique for the Development of Coprocessed Directly Compressible Adjuvant Containing Lactose and Microcrystalline Cellulose," Pharm. Dev. Technol. 8 (2), 143–151 (2003).

11. L. Rambali et al., "Using Experimental Design to Optimize the Process Parameters in Fluidized-Bed Granulation," Drug Dev. Ind. Pharm. 27 (1), 47–55 (2001).

12. S.I. Badway et al., "Effect of Process Parameters on Compressibility of Granulation Manufactured in a High-Shear Mixer," Int. J. Pharm. 198 (1), 51–61 (2000)

13. A. Cannon and K. Shemeley, "Statistical Evaluation of Vial Design Features that Influence Sublimation Rate during Primary Drying," Pharm. Res. 21 (3), 536–542 (2004).

14. W. Sibanda et al., "Experimental Design for the Formulation and Optimization of Novel Cross-Linked Oilispheres Developed for In Vitro Site-Specific Release of Mentha Piperita Oil," AAPS PharmSciTech. 5 (1), E18, 2004.

15. J.Z. Li et al., "The Role of Intra- and Extragranular Microcrystalline Cellulose in Tablet Dissolution," Pharm. Dev. Technol. 1 (4), 343–355 (1996).

16. A.Mckenna and D. F. McCafferty, "Effect of Particle Size on the Compaction Mechanism and Tensile Strength of Tablets," J. Pharm. Pharmacol. 34 (6), 347–351 (1982).

17. R.L. Carr, "Evaluating Flow Properties of Solids," Chem. Eng. 72, 163–168 (1965).

18. "Friability," in USP 24–NF 19 (United States Pharmacopoeial Convention, Rockville, MD, 2000), p. 2148.

19. "Disintegration Time," in USP 24–NF 19 (United States Pharmacopoeial Convention, Rockville, MD, 2000), p. 1941.

20. "Acetaminophen Tablets," in USP 24–NF 19 (United States Pharmacopoeial Convention, Rockville, MD, 2000), p. 20.

21. K.I. Chukwu and O.K. Udeala, "Binding Effectiveness of Colocassia esculenta Gum in Poorly Compressible Drugs: Acetaminophen and Metronidazole Tablet Formulation," Boll. Chim. Farm. 139 (2), 89–97 (2000).

22. S. Mattsson and C. Nystrom, "Evaluation of Critical Binder Properties Affecting the Compactibility of Binary Mixtures," Drug Dev. Ind. Pharm. 27 (3), 181–194 (2001).

23. R.L. Arellano, "Study of Load Capacity of Avicel PH-200 and Cellactose, Two Direct Compression Excipients Using Experimental Design," Drug Dev. Ind. Pharm. 26 (4), 465–469 (2000).

24. S.K. Nachaegari and A.K. Bansal, "Coprocessed Excipients for Solid Dosage Forms," Pharm. Technol. 28 (1), 32–42 (2004).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
20%
To all process for new products only
15%
To select process for new products only
24%
To select processes for both new and legacy products
20%
Do not use QbD
22%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
Overcoming the Challenges in Biopharmaceutical Stability Testing
PhRMA Dismayed by Special 301 Report
FindPharma Custom Search
Source: Pharmaceutical Technology,
Click here